Clinical Infectious Diseases

, volume 76 , issue 7

AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19

Myron J. Levin ¹

Andrew Ustianowski ²

Steven Thomas ³

Alison Templeton ⁴

Yuan Yuan ³

Seth Seegobin ⁴

Catherine F. Houlihan ^{5, 6}

Ibrahim Menendez Perez ⁷

Simon Pollett ^{8, 9}

Rosalinda H. Arends ¹⁰

Rohini Beavon ¹¹

Kanika Dey ¹²

Pedro Garbes ¹²

Elizabeth J. Kelly ¹³

Gavin C K W Koh ¹¹

STEFAN IVANOV ¹⁴

Karen A. Near ¹²

Audrey Sharbaugh ¹⁵

Katie Streicher ¹³

Menelas N. Pangalos ¹⁶

Mark T Esser ¹⁷

Hide authors affiliations Show authors affiliations: 17 affiliations

University of Colorado Denver School of Medicine , Aurora, Colorado , USA |

North Manchester General Hospital , Manchester , United Kingdom |

Biometrics, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA |

⁴

Biometrics, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Cambridge , United Kingdom |

⁵

Department of Clinical Virology, University College London Hospitals National Health Service Foundation Trust , London , United Kingdom |

⁶

Department of Infection and Immunity, University College London , London , United Kingdom |

⁷

Project 4 Research , Miami, Florida , USA |

⁸

Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, Maryland , USA |

⁹

Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc , Bethesda, Maryland , USA |

¹⁰

Clinical Pharmacology and Quantitative Pharmacology, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA |

¹¹

Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Cambridge , United Kingdom |

¹²

Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA |

¹³

Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA |

¹⁴

Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gothenburg , Sweden |

¹⁵

Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Durham, North Carolina , USA |

¹⁶

BioPharmaceuticals Research and Development, AstraZeneca , Cambridge , United Kingdom |

¹⁷

Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA |

Publication type: Journal Article

Publication date: 2022-11-22

Oxford University Press

Clinical Infectious Diseases

scimago Q1

wos Q1

SJR: 2.992

CiteScore: 21.0

Impact factor: 7.3

ISSN: 10584838, 15376591

DOI: 10.1093/cid/ciac899

Copy DOI

PubMed ID: 36411267

Abstract

Background

We report primary results of a phase 3 trial of AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis to prevent symptomatic coronavirus disease 2019 (COVID-19)

Methods

Adults without prior SARS-CoV-2 infection or COVID-19 vaccination were enrolled within 8 days of exposure to a SARS-CoV-2–infected individual and randomized 2:1 to a single 300-mg AZD7442 dose (one 1.5-mL intramuscular injection each of tixagevimab and cilgavimab consecutively) or placebo. Primary endpoints were safety and first post-dose SARS-CoV-2 reverse-transcription–polymerase-chain-reaction (RT-PCR)–positive symptomatic COVID-19 event before day 183.

Results

1121 participants were randomized and dosed (mean age 46 years; 49% females; AZD7442, n=749; placebo, n=372). Median (range) follow-up was 49 (5–115) and 48 (20–113) days for AZD7442 and placebo, respectively. Adverse events occurred in 162/749 (21.6%) and 111/372 (29.8%) participants with AZD7442 and placebo, respectively, mostly mild/moderate. RT-PCR–positive symptomatic COVID-19 occurred in 23/749 (3.1%) and 17/372 (4.6%) AZD7442- and placebo-treated participants, respectively (relative risk reduction 33.3%; 95% confidence interval [CI] –25.9 to 64.7; P=.21). In predefined subgroup analyses of 1073 (96%) participants who were SARS-CoV-2 RT-PCR–negative (n=974 [87%]) or missing an RT-PCR result (n=99 [9%]) at baseline, AZD7442 reduced RT-PCR–positive symptomatic COVID-19 by 73.2% (95% CI 27.1 to 90.1) versus placebo.

Conclusions

This study did not meet the primary efficacy endpoint of post-exposure prevention of symptomatic COVID-19 with AZD7442 versus placebo. However, predefined analysis of participants who were SARS-CoV-2 RT-PCR–negative or missing an RT-PCR result at baseline support a role for AZD7442 in preventing symptomatic COVID-19.

Found

1 citation

Itoh Yohji

35 publications, 2 589 citations

h-index: 16

Top-30

Journals

	1
Expert Opinion on Biological Therapy	Expert Opinion on Biological Therapy, 1, 3.7% Expert Opinion on Biological Therapy 1 publication, 3.7%
Nauchno-Prakticheskaya Revmatologiya	Nauchno-Prakticheskaya Revmatologiya, 1, 3.7% Nauchno-Prakticheskaya Revmatologiya 1 publication, 3.7%
International Journal of Infectious Diseases	International Journal of Infectious Diseases, 1, 3.7% International Journal of Infectious Diseases 1 publication, 3.7%
Open Forum Infectious Diseases	Open Forum Infectious Diseases, 1, 3.7% Open Forum Infectious Diseases 1 publication, 3.7%
Journal of the Formosan Medical Association	Journal of the Formosan Medical Association, 1, 3.7% Journal of the Formosan Medical Association 1 publication, 3.7%
Frontiers in Cellular and Infection Microbiology	Frontiers in Cellular and Infection Microbiology, 1, 3.7% Frontiers in Cellular and Infection Microbiology 1 publication, 3.7%
Pharmaceuticals	Pharmaceuticals, 1, 3.7% Pharmaceuticals 1 publication, 3.7%
Transplant Infectious Disease	Transplant Infectious Disease, 1, 3.7% Transplant Infectious Disease 1 publication, 3.7%
European Journal of Medical Research	European Journal of Medical Research, 1, 3.7% European Journal of Medical Research 1 publication, 3.7%
International Journal of Rheumatic Diseases	International Journal of Rheumatic Diseases, 1, 3.7% International Journal of Rheumatic Diseases 1 publication, 3.7%
Journal of the Pediatric Infectious Diseases Society	Journal of the Pediatric Infectious Diseases Society, 1, 3.7% Journal of the Pediatric Infectious Diseases Society 1 publication, 3.7%
Bioanalysis	Bioanalysis, 1, 3.7% Bioanalysis 1 publication, 3.7%
Viruses	Viruses, 1, 3.7% Viruses 1 publication, 3.7%
Antimicrobial Agents and Chemotherapy	Antimicrobial Agents and Chemotherapy, 1, 3.7% Antimicrobial Agents and Chemotherapy 1 publication, 3.7%
Microorganisms	Microorganisms, 1, 3.7% Microorganisms 1 publication, 3.7%
Leukemia and Lymphoma	Leukemia and Lymphoma, 1, 3.7% Leukemia and Lymphoma 1 publication, 3.7%
Cell Chemical Biology	Cell Chemical Biology, 1, 3.7% Cell Chemical Biology 1 publication, 3.7%
Infectious Diseases and Therapy	Infectious Diseases and Therapy, 1, 3.7% Infectious Diseases and Therapy 1 publication, 3.7%
Clinical Microbiology Reviews	Clinical Microbiology Reviews, 1, 3.7% Clinical Microbiology Reviews 1 publication, 3.7%
Vaccines	Vaccines, 1, 3.7% Vaccines 1 publication, 3.7%
Russian Chemical Reviews	Russian Chemical Reviews, 1, 3.7% Russian Chemical Reviews 1 publication, 3.7%
Journal of Infection and Chemotherapy	Journal of Infection and Chemotherapy, 1, 3.7% Journal of Infection and Chemotherapy 1 publication, 3.7%
Virology Journal	Virology Journal, 1, 3.7% Virology Journal 1 publication, 3.7%
Clinical Pharmacology in Drug Development	Clinical Pharmacology in Drug Development, 1, 3.7% Clinical Pharmacology in Drug Development 1 publication, 3.7%
Anesteziologiya i Reanimatologiya	Anesteziologiya i Reanimatologiya, 1, 3.7% Anesteziologiya i Reanimatologiya 1 publication, 3.7%
	1

Publishers

	1 2 3 4
Elsevier	Elsevier, 4, 14.81% Elsevier 4 publications, 14.81%
MDPI	MDPI, 4, 14.81% MDPI 4 publications, 14.81%
Taylor & Francis	Taylor & Francis, 3, 11.11% Taylor & Francis 3 publications, 11.11%
Wiley	Wiley, 3, 11.11% Wiley 3 publications, 11.11%
Springer Nature	Springer Nature, 3, 11.11% Springer Nature 3 publications, 11.11%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 2, 7.41% Cold Spring Harbor Laboratory 2 publications, 7.41%
Oxford University Press	Oxford University Press, 2, 7.41% Oxford University Press 2 publications, 7.41%
American Society for Microbiology	American Society for Microbiology, 2, 7.41% American Society for Microbiology 2 publications, 7.41%
Mediar Press	Mediar Press, 1, 3.7% Mediar Press 1 publication, 3.7%
Frontiers Media S.A.	Frontiers Media S.A., 1, 3.7% Frontiers Media S.A. 1 publication, 3.7%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii	Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii, 1, 3.7% Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii 1 publication, 3.7%
Media Sphere Publishing House	Media Sphere Publishing House, 1, 3.7% Media Sphere Publishing House 1 publication, 3.7%
	1 2 3 4

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Levin M. J. et al. AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19 // Clinical Infectious Diseases. 2022. Vol. 76. No. 7.

GOST all authors (up to 50) Copy

Levin M. J., Ustianowski A., Thomas S., Templeton A., Yuan Y., Seegobin S., Houlihan C. F., Menendez Perez I., Pollett S., Arends R. H., Beavon R., Dey K., Garbes P., Kelly E. J., Koh G. C. K. W., IVANOV S., Near K. A., Sharbaugh A., Streicher K., Pangalos M. N., Esser M. T. AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19 // Clinical Infectious Diseases. 2022. Vol. 76. No. 7.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1093/cid/ciac899

UR - https://doi.org/10.1093/cid/ciac899

TI - AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19

T2 - Clinical Infectious Diseases

AU - Levin, Myron J.

AU - Ustianowski, Andrew

AU - Thomas, Steven

AU - Templeton, Alison

AU - Yuan, Yuan

AU - Seegobin, Seth

AU - Houlihan, Catherine F.

AU - Menendez Perez, Ibrahim

AU - Pollett, Simon

AU - Arends, Rosalinda H.

AU - Beavon, Rohini

AU - Dey, Kanika

AU - Garbes, Pedro

AU - Kelly, Elizabeth J.

AU - Koh, Gavin C K W

AU - IVANOV, STEFAN

AU - Near, Karen A.

AU - Sharbaugh, Audrey

AU - Streicher, Katie

AU - Pangalos, Menelas N.

AU - Esser, Mark T

PY - 2022

DA - 2022/11/22

PB - Oxford University Press

IS - 7

VL - 76

PMID - 36411267

SN - 1058-4838

SN - 1537-6591

ER -

BibTex

Cite this

BibTex (up to 50 authors) Copy

@article{2022_Levin,

author = {Myron J. Levin and Andrew Ustianowski and Steven Thomas and Alison Templeton and Yuan Yuan and Seth Seegobin and Catherine F. Houlihan and Ibrahim Menendez Perez and Simon Pollett and Rosalinda H. Arends and Rohini Beavon and Kanika Dey and Pedro Garbes and Elizabeth J. Kelly and Gavin C K W Koh and STEFAN IVANOV and Karen A. Near and Audrey Sharbaugh and Katie Streicher and Menelas N. Pangalos and Mark T Esser},

title = {AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19},

journal = {Clinical Infectious Diseases},

year = {2022},

volume = {76},

publisher = {Oxford University Press},

month = {nov},

url = {https://doi.org/10.1093/cid/ciac899},

number = {7},

doi = {10.1093/cid/ciac899}

}

Publisher

Oxford University Press

Journal

Clinical Infectious Diseases

scimago Q1

wos Q1

SJR

2.992

CiteScore

21.0

Impact factor

7.3

ISSN

10584838 (Print)

15376591 (Electronic)